Drug Profile
Filgrastim transdermal - Zosano Pharma
Alternative Names: ZP-G-CSFLatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Zosano Pharma
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neutropenia in USA (Transdermal, Patch)
- 21 Jan 2009 Preclinical trials in Neutropenia in USA (Transdermal)